Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein

Multiple Sclerosis Journal

Volumn 18, Issue 4, 2012, Pages 398-408

  Herges, Katja ^a   De Jong, Brigit A ^b   Kolkowitz, Ilan ^a   Dunn, Caitlin ^a   Mandelbaum, Gil ^a   Ko, Rose M ^c   Maini, Alexander ^a   Han, May H ^a   Killestein, Joep ^d   Polman, Chris ^d   Goodyear, Alexandra L ^a   Dunn, Jeffrey ^a   Steinman, Lawrence ^a   Axtell, Robert C ^a  

^a STANFORD UNIVERSITY   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

experimental autoimmune encephalomyelitis; multiple sclerosis; neutrophil elastase; neutrophil elastase inhibitor; Th17 cells

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CHEMOKINE; COMPLEMENT COMPONENT C5A; ELASTASE INHIBITOR; GLATIRAMER; LEUKOCYTE ELASTASE; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB; SIVELESTAT;

ADOPTIVE TRANSFER; ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; GRANULOCYTE; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NEUTROPHIL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; RELAPSE; REMISSION; SPINAL CORD; SPLEEN CELL; TH1 CELL; TH17 CELL; TREATMENT OUTCOME;

EID: 84859385976     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512440060     Document Type: Article

References (34)

1. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 ; 125 (Pt 7). 1450-1461
2. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006 ; 77 (9). 1073-1075
3. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 ; 63: 964-968
4. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007 ; 4: e133
5. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005 ; 128: 988-1002
6. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010 ; 16: 1443-1452
7. Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011 ; 18: 1313-1317
8. Zhang Z, Zhong W, Spencer D, et al. Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine. 2009 ; 46: 79-91
9. Liang SC, Long AJ, Bennett F, et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol. 2007 ; 179: 7791-7799
10. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008 ; 205: 1535-1541
11. Uzawa A, Mori M, Hayakawa S, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol. 2010 ; 17: 672-676
12. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010 ; 67: 1016-1017
13. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN beta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010 ; 75: 1423-1427
14. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007 ; 252: 57-61
15. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010 ; 16: 406-412
16. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 ; 53 (5). 1107-1114
17. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997 ; 120 (11). 2059-2069
18. Tintoré M, Rovira A, Martínez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000 ; 21 (4). 702-706
19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66 (10). 1485-1489
20. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011 ; 187: 490-500
21. Walz A, Burgener R, Car B, et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991 ; 174: 1355-1362
22. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003 ; 421: 744-748
23. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005 ; 201: 233-240
24. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003 ; 197: 711-723
25. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005 ; 202: 135-143
26. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med. 2008 ; 14 (3). 337-342
27. Kawabata K, Suzuki M, Sugitani M, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 ; 177: 814-820
28. Inoue Y, Tanaka H, Ogura H, et al. A neutrophil elastase inhibitor, Sivelestat, improves leukocyte deformability in patients with acute lung injury. J Trauma. 2006 ; 60: 943
29. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009 ; 65: 499-509
30. Prinz M, Kalinke U. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med. 2010 ; 16: 379-386
31. Ramgolam VS, Sha Y, Jin J, et al. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009 ; 183: 5418-5427
32. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008 ; 172: 146-155
33. Werner JL, Gessner MA, Lilly LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infect Immun. 2011 ; 79: 3966-3977
34. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010 ; 33: 657-670